Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Ambrisentan
DRUG: Placebo
DRUG: Sildenafil
DRUG: Tadalafil

Sponsor

Gilead Sciences